Literature DB >> 14706487

Attention-deficit/hyperactivity disorder: cognitive evoked potential (P300) topography predicts treatment response to methylphenidate.

R Bart Sangal1, JoAnne M Sangal.   

Abstract

OBJECTIVE: Auditory cognitive evoked potential (P300) topography predicts robust response to the stimulant pemoline in patients with attention-deficit/hyperactivity disorder (ADHD). Patients with a right fronto-central to parietal (FC2:P4) auditory P300 amplitude ratio >0.5 respond robustly to pemoline, whereas others do not. This study was performed to demonstrate whether the same test and ratio predict treatment response to methylphenidate.
METHODS: Patients aged 6-12 with DSM-IV diagnosis of ADHD were administered auditory and visual cognitive evoked potential (P300) testing. They then underwent single-blind treatment with an extended-release version of methylphenidate. Robust response was defined as a 60% decrease from baseline in a parent rated ADHD rating scale.
RESULTS: Nine of 20 subjects responded robustly. They did not differ from the non-robust responders in age, baseline attention or hyperactivity ratings, or any P300 parameter except auditory P300 topography. A FC2:P4 auditory P300 amplitude ratio >0.5 predicted robust response with a positive predictive value of 0.67 and a negative predictive value of 0.73.
CONCLUSIONS: The ratio of right fronto-central to parietal auditory P300 amplitude predicts response to stimulants in patients with ADHD. As non-stimulant treatments are approved for the treatment of ADHD, tests such as this may help pinpoint whether to use a stimulant or a medicine with some other mechanism of action.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14706487     DOI: 10.1016/j.clinph.2003.08.023

Source DB:  PubMed          Journal:  Clin Neurophysiol        ISSN: 1388-2457            Impact factor:   3.708


  6 in total

1.  Neuroimaging-Aided Prediction of the Effect of Methylphenidate in Children with Attention-Deficit Hyperactivity Disorder: A Randomized Controlled Trial.

Authors:  Ayaka Ishii-Takahashi; Ryu Takizawa; Yukika Nishimura; Yuki Kawakubo; Kasumi Hamada; Shiho Okuhata; Shingo Kawasaki; Hitoshi Kuwabara; Takafumi Shimada; Ayako Todokoro; Takashi Igarashi; Kei-Ichiro Watanabe; Hidenori Yamasue; Nobumasa Kato; Kiyoto Kasai; Yukiko Kano
Journal:  Neuropsychopharmacology       Date:  2015-05-04       Impact factor: 7.853

2.  Effects of methylphenidate on the ERP amplitude in youth with ADHD: A double-blind placebo-controlled cross-over EEG study.

Authors:  Mica Rubinson; Itai Horowitz; Jodie Naim-Feil; Doron Gothelf; Nava Levit-Binnun; Elisha Moses
Journal:  PLoS One       Date:  2019-05-31       Impact factor: 3.240

Review 3.  Sensory processing and P300 event-related potential correlates of stimulant response in children with attention-deficit/hyperactivity disorder: A critical review.

Authors:  Virginia Peisch; Tara Rutter; Carol L Wilkinson; Anne B Arnett
Journal:  Clin Neurophysiol       Date:  2021-02-05       Impact factor: 3.708

4.  Predicting the clinical outcome of stimulant medication in pediatric attention-deficit/hyperactivity disorder: data from quantitative electroencephalography, event-related potentials, and a go/no-go test.

Authors:  Geir Ogrim; Juri Kropotov; Jan Ferenc Brunner; Gian Candrian; Leiv Sandvik; Knut A Hestad
Journal:  Neuropsychiatr Dis Treat       Date:  2014-02-03       Impact factor: 2.570

5.  Altered Auditory P300 Performance in Parents with Attention Deficit Hyperactivity Disorder Offspring.

Authors:  Mei Hung Chi; Ching-Lin Chu; I Hui Lee; Yi-Ting Hsieh; Ko Chin Chen; Po See Chen; Yen Kuang Yang
Journal:  Clin Psychopharmacol Neurosci       Date:  2019-11-20       Impact factor: 2.582

6.  A Signature of Attention-Elicited Electrocortical Activity Distinguishes Response From Non-Response to the Non-Stimulant Atomoxetine in Children and Adolescents With ADHD.

Authors:  Kristi R Griffiths; Barbora G Jurigova; John E Leikauf; Donna Palmer; Simon D Clarke; Tracey W Tsang; Erdahl T Teber; Michael R Kohn; Leanne M Williams
Journal:  J Atten Disord       Date:  2017-10-03       Impact factor: 3.256

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.